Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 8/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.33 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13523800 | 1.00 | POLB (0.39) | POLBMEN1USP2KMT2AP2RY2 | |
| SCHEMBL13671118 | 1.00 | POLB (0.39) | POLBMEN1USP2KMT2AP2RY2 | |
| SCHEMBL15281799 | 0.95 | POLB (0.41) | POLBMEN1USP2KMT2AP2RY2 | |
| SCHEMBL13592886 | 0.95 | POLB (0.41) | POLBMEN1USP2KMT2AP2RY2 | |
| SCHEMBL14215483 | 0.90 | TDP1 (0.39) | P2RY2TDP1P2RY4P2RY6 | |
| SCHEMBL14188189 | 0.90 | TDP1 (0.39) | P2RY2TDP1P2RY4P2RY6 | |
| SCHEMBL13523539 | 0.89 | POLB (0.41) | POLBMEN1USP2KMT2AP2RY2 | |
| SCHEMBL13523533 | 0.89 | POLB (0.41) | POLBMEN1USP2KMT2AP2RY2 | |
| SCHEMBL13523797 | 0.89 | POLB (0.41) | POLBMEN1USP2KMT2AP2RY2 | |
| SCHEMBL21418943 | 0.88 | POLB (0.36) | POLBMEN1USP2KMT2AP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648054-B2 | 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication | ROCHE PALO ALTO LLC (US) | 2014-02-11 | — | — | US | disclosed |
| US-20130237491-A1 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | ROCHE PALO ALTO LLC (US) | 2013-09-12 | — | — | US | disclosed |
| US-8071567-B2 | 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication | ROCHE PALO ALTO LLC (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071567-B2 | 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication | ROCHE PALO ALTO LLC (US) | 2011-12-06 | — | — | US | disclosed |
| US-20100003213-A1 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | DEVOS RENE ROBERT | 2010-01-07 | — | — | US | disclosed |
| US-20100003213-A1 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | DEVOS RENE ROBERT | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003213-A1 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | NSUN2, RNGTT, RNMT | POLB 93/4885MEN1 4819/4885USP2 3879/4885 |
| US-20130237491-A1 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | NSUN2, RNGTT, RNMT | POLB 93/4885MEN1 4819/4885USP2 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.